Scarica l'app Stockscreener
3.10
6.20%
-0.205
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Clene Inc Borsa (CLNN) Ultime notizie
Two parties report shared voting power over 221,660 shares in Clene (CLNN). - Stock Titan
A $4 million raise is expected to carry an ALS biotech past a potential FDA decision - Stock Titan
Insider-linked LLC acquires new Clene (CLNN) shares - Stock Titan
Clene (CLNN) CEO buys more stock in board-approved deal - Stock Titan
Insiders back new funding round at Clene Inc. (CLNN) to support lead drug filing - Stock Titan
A biotech's $4 million stock offering is expected to fund operations into 2027 - Stock Titan
Clene at cantorfitzgerald global healthcare conference: ALS drug nears filing By Investing.com - Investing.com Canada
Clene at cantorfitzgerald global healthcare conference: ALS drug nears filing By Investing.com - Investing.com India
Clene at cantorfitzgerald global healthcare conference: ALS drug nears filing By Investing.com - Investing.com UK
Clene to Present at Upcoming September Investor Conferences - Investing News Network
Clene to Present at Upcoming September Investor Conferences - manilatimes.net
Two investor conferences in New York will hear from Clene this month - Stock Titan
CLENE Q2 BASIC EPS USD -1.08 - Moomoo
Clene (CLNN) Financial Results: EPS Prints Above Forecast in the Latest Reading; Trading Move: Shares Finish 1.14% Down at the CloseNext Quarter Guidance - vinanet.vn
Analysts’ Top Consumer Goods Picks: Kimberly Clark (KMB), Clene (CLNN) - The Globe and Mail
Clene (CLNN) Outlook: Adds 4.30% to Close at $4.37 at the Close; Price Context: the Near-Term Reference Band Stretches From $4.15 to $4.59 under the Current SnapshotQuote Data - vinanet.vn
Clene Eyes Q4 NDA for ALS Drug After FDA-Requested Biomarker Analyses - MarketBeat
Clene Eyes Q4 NDA for ALS Drug After FDA-Requested Biomarker Analyses - Yahoo Finance
Clene at Emerging Growth Conference: FDA path takes shape for ALS drug - Investing.com
CLNN: CNM-Au8 shows strong survival and functional benefits in ALS, with NDA submission imminent - TradingView
Clene (CLNN) Move: Climbs 0.49% to $4.11 on the Day; Technical Setup: $3.90 and $4.32 Define the Nearby Reference Levels for the Current SessionVWAP Deviation - vinanet.vn
Presenting on Emerging Growth Conference 95 Day 1 on August 19; Register to live stream - Investing News Network
HC Wainwright Issues Negative Estimate for Clene Earnings - MarketBeat
Clene (NasdaqCM:CLNN) Stock Forecast & Analyst Predictions - simplywall.st
Clene(CLNN) Stock Options Chain | Quotes & News - Moomoo
Clene to Present at the Emerging Growth Conference - Investing News Network
Clene stock holds at buy as H.C. Wainwright keeps $31 target By Investing.com - Investing.com Australia
Clene to Present at the Emerging Growth Conference - marketscreener.com
Clene schedules a 3:10 p.m. webcast—what will it cover? - Stock Titan
Clene stock holds at buy as H.C. Wainwright keeps $31 target - Investing.com
Clene stock holds at buy as H.C. Wainwright keeps $31 target - Investing.com Australia
Clene stock holds at buy as H.C. Wainwright keeps $31 target - Investing.com Nigeria
Clene stock holds at buy as H.C. Wainwright keeps $31 target - Investing.com Canada
Clene stock holds at buy as H.C. Wainwright keeps $31 target - Investing.com
Clene to Present at the Emerging Growth Conference - The Manila Times
Clene (NASDAQ:CLNN): Why Is Evidence And Funding in Focus Today? - Kalkine Media
Clene (NASDAQ:CLNN): Why Is Clinical Evidence in Focus Today? - Kalkine Media
CLNN Looks 375.9% Overvalued on GF Value™ - GuruFocus
Clene earnings missed by $0.75, revenue topped estimates - Investing.com
Clene (NASDAQ:CLNN) Announces Quarterly Earnings Results, Misses Estimates By $0.71 EPS - MarketBeat
Clene Releases Q2 2026 Financial Results - AlphaStreet
Vivo Opportunity entities disclose 9.99% Clene Inc. (CLNN) stake via warrants - Stock Titan
Clene Inc. (CLNN) grants 3,195 stock options to director Matthew Kiernan - Stock Titan
Clene Inc. (CLNN) grants 4,872 stock options to director Alison Mosca - Stock Titan
Clene Inc. (CLNN) grants director Arjun Desai 3,674 options at $4.19 strike - Stock Titan
Clene Inc. (CLNN) director receives 6,230 stock options at $4.19 strike - Stock Titan
Clene Inc. (CLNN) awards director Shalom Jacobovitz 4,752 stock options at $4.19 - Stock Titan
Clene Inc. (CLNN) director receives 3,514 stock options vesting immediately at $4.19 - Stock Titan
Clene Inc. (CLNN) director granted 3,514 stock options at $4.19 strike - Stock Titan
Clene Q2 FY26 net loss widens 81% to $13.42 million - Bitget
4.22%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):